Abdullah Alsuhaibani1, Ahmed Elashwah2,3, Rana Mahmood2, Alaa Abduljabbar4, Samar Alhomoud4, Luai Ashari4, Shouki Bazarbashi5, Ali Aljubran5, Ahmed Alzahrani5, Muhamed Mohiuddin2, Hadeel Almanea6, Hussah Alhussaini6, Nasser AlSanea4. 1. Oncology Center ,University Medical City, King Saud University, Riyadh, Saudi Arabia. asuhaibani@gmail.com. 2. Section of Radiation Oncology, King Faisal Specialist Hospital & Research Centre, Riyadh, Saudi Arabia. 3. Kasr Al-Eini Center of Clinical Oncology (NEMROCK), Cairo University, Cairo, Egypt. 4. Section of Colon and Rectal Surgery, King Faisal Specialist Hospital & Research Centre, Riyadh, Saudi Arabia. 5. Section of Medical Oncology, King Faisal Specialist Hospital & Research Centre, Riyadh, Saudi Arabia. 6. Pathology and Laboratory Medicine, King Faisal Specialist Hospital & Research Centre, Riyadh, Saudi Arabia.
Abstract
PURPOSE: Assess feasibility-rate of PCR, short-term toxicity after neoadjuvant concurrent chemoradiation (NACRT) delivered via simultaneous integrated boost (SIB) using volumetric modulated arc therapy (VMAT) technique for locally advanced rectal cancer. METHODS: Retrospective evaluation of patients with locally advanced rectal cancer treated with VMAT-SIB technique preoperatively at an academic tertiary care center in Riyadh, Saudi Arabia between February 2013 and March 2017. RESULTS: One hundred patients with depth of invasion staged as T3/T4 or T2 in 93 and seven patients, respectively. Lymph node metastasis was staged as N1/N2 or N0 in 87 and 13 patients, respectively. Circumferential radial margin (CRM) was involved radiologically prior to treatment in 50 patients. A dose of 55 or 50 Gy was given to 71 and 29 patients, respectively. All treatments were completed without interruption. Grade 3/4 toxicity was not observed. Low anterior resection and abdominoperineal resection were performed with negative proximal, distal, and radial margins in 72 and 28 patients, respectively. There were no immediate significant postoperative complications. Histologically, no residual tumor (grade 0) was noted in 20 patients (pCR). Regression grade 1, 2, and 3 were noted in 31, 34, and 15 patients. Average number of lymph nodes retrieved in the surgical specimen was 12 (range 6-22). Lymph nodes were negative for cancer in 80 patients. CONCLUSION: Dose escalation with SIB-VMAT as NACRT for rectal cancer is feasible. Moreover, it can increase the rate of pathological complete response with a favorable toxicity profile. Clinical benefit of this approach needs to be validated in a larger cohort of patients with longer follow-up.
PURPOSE: Assess feasibility-rate of PCR, short-term toxicity after neoadjuvant concurrent chemoradiation (NACRT) delivered via simultaneous integrated boost (SIB) using volumetric modulated arc therapy (VMAT) technique for locally advanced rectal cancer. METHODS: Retrospective evaluation of patients with locally advanced rectal cancer treated with VMAT-SIB technique preoperatively at an academic tertiary care center in Riyadh, Saudi Arabia between February 2013 and March 2017. RESULTS: One hundred patients with depth of invasion staged as T3/T4 or T2 in 93 and seven patients, respectively. Lymph node metastasis was staged as N1/N2 or N0 in 87 and 13 patients, respectively. Circumferential radial margin (CRM) was involved radiologically prior to treatment in 50 patients. A dose of 55 or 50 Gy was given to 71 and 29 patients, respectively. All treatments were completed without interruption. Grade 3/4 toxicity was not observed. Low anterior resection and abdominoperineal resection were performed with negative proximal, distal, and radial margins in 72 and 28 patients, respectively. There were no immediate significant postoperative complications. Histologically, no residual tumor (grade 0) was noted in 20 patients (pCR). Regression grade 1, 2, and 3 were noted in 31, 34, and 15 patients. Average number of lymph nodes retrieved in the surgical specimen was 12 (range 6-22). Lymph nodes were negative for cancer in 80 patients. CONCLUSION: Dose escalation with SIB-VMAT as NACRT for rectal cancer is feasible. Moreover, it can increase the rate of pathological complete response with a favorable toxicity profile. Clinical benefit of this approach needs to be validated in a larger cohort of patients with longer follow-up.
Authors: Rolf Sauer; Heinz Becker; Werner Hohenberger; Claus Rödel; Christian Wittekind; Rainer Fietkau; Peter Martus; Jörg Tschmelitsch; Eva Hager; Clemens F Hess; Johann-H Karstens; Torsten Liersch; Heinz Schmidberger; Rudolf Raab Journal: N Engl J Med Date: 2004-10-21 Impact factor: 91.245
Authors: N A Janjan; C Crane; B W Feig; K Cleary; R Dubrow; S Curley; J N Vauthey; P Lynch; L M Ellis; R Wolff; R Lenzi; J Abbruzzese; R Pazdur; P M Hoff; P Allen; T Brown; J Skibber Journal: Am J Clin Oncol Date: 2001-04 Impact factor: 2.339
Authors: Vincenzo Valentini; Regina Beets-Tan; Josep M Borras; Zoran Krivokapić; Jan Willem Leer; Lars Påhlman; Claus Rödel; Hans Joachim Schmoll; Nigel Scott; Cornelius Van de Velde; Christine Verfaillie Journal: Radiother Oncol Date: 2008-06-03 Impact factor: 6.280
Authors: M J Gallagher; H D Brereton; R A Rostock; J M Zero; D A Zekoski; L F Poyss; M P Richter; M M Kligerman Journal: Int J Radiat Oncol Biol Phys Date: 1986-09 Impact factor: 7.038